Biotechnology company Antag Therapeutics has revealed promising results from its novel GIPR antagonist for the treatment of obesity. 

AT7687, a first-in-class GIPR antagonist, was trialled in a Phase I randomised, double-blind, placebo-controlled study. Results show AT7687 demonstrated a favourable safety and tolerability profile across all doses. 

The novel treatment was also combined with cagrilintide, showing robust and sustained weight loss without evidence that the effect plateaued over time. This weight loss effect was superior to that of either monotherapy treatment. 

The combination was also associated with favourable changes in body composition, including preferential loss of fat mass relative to lean mass, as well as improvements in insulin sensitivity, supporting a differentiated and synergistic profile versus amylin treatment alone.

The data builds on results already reported by Antag demonstrating AT7687’s additive effect on weight loss, body composition, insulin sensitivity and CV risk biomarkers when combined with GLP-1 agonist liraglutide. 

“These combination data with cagrilintide, building on those already reported with liraglutide, demonstrate AT7687’s leading combination partner of choice status in the obesity field,” said Jörg Möller, Chief Executive Officer of Antag Therapeutics. 

“The potential for AT7687 to not only enhance weight loss but also have strong additive effect on both healthier body composition and insulin sensitivity, without increasing the tolerability burden, is especially compelling in this insulin-resistant study group.  

“With its excellent and highly differentiated PK/PD profile and absence of GI effects reported in our Phase I study, Antag is perfectly positioned to advance this highly differentiated asset into Phase II development.”

Bruno Quinney, Content Team, DDW